TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
An analysis of prospectively logged menstrual cycles found that users of a combined GLP-1/GIP receptor agonist had a larger average reduction in cycle length and lower cycle variability than GLP-1-only users and never-users. The observational findings, presented at the American Society for Reproductive Medicine meeting, do not establish that the medication caused the changes.
An analysis presented at the American Society for Reproductive Medicine’s annual meeting found that women reporting use of a combined GLP-1/GIP receptor agonist had a larger reduction in menstrual cycle length and lower cycle variability than women using a GLP-1 drug alone or never-users. The prospective cohort findings suggest a possible link between incretin medicines and menstrual regularity, but they do not show that the drugs caused the changes.
The researchers analyzed 1,945 participants in the Apple Women’s Health Study, who had logged a total of 70,134 menstrual cycles. Of those participants, 123 reported using a combined GLP-1/GIP medicine in the past year, 258 reported GLP-1 medication use, and 1,564 were never-users. Participants were younger than 50, were not pregnant or lactating or using hormones, and had logged at least three cycles.
Compared with the groups’ reported baseline measurements, mean cycle length fell by 2.5 days among combined-drug users, 0.4 days among GLP-1 users, and 0.8 days among never-users. Mean individual cycle variability was 6.93 days for combined-drug users, versus 7.45 days for GLP-1 users and 7.46 days for never-users. The figures describe associations in this analysis; they are not evidence that the medication produced the changes.
A subgroup analysis of participants with polyendocrine metabolic ovarian syndrome (PMOS), the name used in the report for the condition formerly called polycystic ovary syndrome, showed greater differences in cycle variability: 5.80 days among combined-drug users, 7.34 days among GLP-1 users, and 9.45 days among never-users. The study’s authors reported that medication groups differed in some characteristics, including age, parity, and the prevalence of PMOS and other health conditions.
Cycle Patterns and Ovarian Health
Menstrual regularity can matter to people trying to conceive, but its relevance extends beyond fertility. Irregular periods can also be a signal of underlying health issues, said Rachel Weinerman, an ob/gyn and reproductive endocrinologist at Case Western Reserve University who was not involved in the study, in comments to MedPage Today.
The results may be relevant because incretin medicines are widely used for weight management and metabolic conditions. The report says more than 10 million women in the United States use either a GLP-1 or combined GLP-1/GIP receptor agonist. Still, the analysis does not establish a reason to prescribe these drugs to regulate cycles. It raises a research question about whether changes in weight or broader metabolic health, or other biological effects, could be associated with menstrual patterns.
The subgroup results also point to the possibility that people with PMOS may have different responses from other participants. That possibility is not proof of a separate drug effect: the analysis was observational, and the groups were not identical at the outset. The findings could help guide further study, but clinical decisions require evidence beyond this association.
Products Worth Considering
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Oral-B iO5 Rechargeable Electric Toothbrush with 5 Cleaning Modes
As an affiliate, we earn on qualifying purchases.
How the Cohort Tracked Cycles
The Apple Women’s Health Study is a longitudinal digital cohort of about 147,000 U.S. women. Participants in this analysis consented to share menstrual-cycle logs recorded through Apple HealthKit and answered surveys about medication use, demographics, and medical history. The researchers used the logged cycle information, not sensor-based data.
The report describes this as an effort to examine cycle length and variability prospectively. Earlier retrospective studies had suggested a possible association between these medicines and more regular periods, but, according to the report, this analysis treated menstrual-cycle measures as the primary focus. The researchers grouped participants by reported use in the past year; the study did not randomly assign medication.
The only GLP-1/GIP medicine approved by the U.S. Food and Drug Administration, according to the report, is tirzepatide, marketed as Zepbound. GLP-1 medicines and combined GLP-1/GIP medicines act through different mechanisms. The reported analysis pooled medication use by category and did not provide results for individual drugs.
““This more pronounced reduction among PMOS individuals might suggest a separate pathway that might focus on ovulatory health in addition to those metabolic parameters that support ovulation, but further research is necessary.””
— Shruthi Mahalingaiah, MD, MS, of the Harvard T.H. Chan School of Public Health, as quoted by MedPage Today
Cause and Drug Effects Remain Unknown
The analysis cannot show that incretin medication caused the cycle changes. Medication use was self-reported, participants were not assigned treatments, and the study groups differed on some baseline characteristics. Factors such as weight change, the reason for treatment, and underlying health conditions could be related both to medication use and to menstrual patterns.
The report does not provide the change in cycle length for the PMOS subgroup, nor does it establish whether the observed differences affected ovulation, fertility, or other health outcomes. It also does not give drug-specific results for the combined-treatment group. The researchers said they plan future reports that will examine individual agents. Until more evidence is available, the size and cause of any medication-related effect remain uncertain.
Researchers Plan Drug-Specific Results
Mahalingaiah said future manuscripts will break down the data by particular medicines. That could clarify whether the association differs among individual agents, though a drug-specific analysis of the same cohort would still not by itself prove cause and effect.
Further research would be needed to test whether the patterns hold in other groups and to investigate possible explanations, including weight loss and metabolic or direct ovarian effects. The meeting presentation reports an association; it does not change the approved uses of the medicines. People taking or considering these drugs should discuss treatment and menstrual changes with a qualified clinician rather than using them specifically to regulate periods.
Key Questions
What did the analysis find?
Users of a combined GLP-1/GIP receptor agonist had a 2.5-day reduction in mean cycle length, compared with reductions of 0.4 days among GLP-1 users and 0.8 days among never-users. Their mean cycle variability was also lower in the reported analysis.
Does this prove the medication makes periods more regular?
No. The study was observational, so it found an association, not proof that the medication caused the cycle changes. The groups differed in some characteristics, and other factors could help explain the results.
What did the PMOS subgroup show?
Mean individual cycle variability was 5.80 days among combined-drug users with PMOS, 7.34 days among GLP-1 users, and 9.45 days among never-users. The report said further research is needed to explain the pattern.
Were results reported for individual drugs?
No. The analysis grouped participants by medication type. Mahalingaiah said future manuscripts will break down the data by particular agents.
Source: medpagetoday.com
